1. Home
  2. SLGL

as of 06-05-2026 12:21pm EST

$75.40
+$1.03
+1.38%
Stocks Health Care Biotechnology: Pharmaceutical Preparations Nasdaq

Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.

Founded: 1997 Country:
Israel
Israel
Employees: N/A City: N/A
Market Cap: 247.1M IPO Year: 2016
Target Price: $110.00 AVG Volume (30 days): 25.0K
Analyst Decision: Strong Buy Number of Analysts: 1
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: N/A EPS Growth: N/A
52 Week Low/High: $6.80 - $97.97 Next Earning Date: 05-22-2026
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): -72.22% Revenue Growth (next year): 223.84%
P/E Ratio: N/A Index: N/A
Free Cash Flow: N/A FCF Growth: N/A

Stock Insider Trading Activity of Sol-Gel Technologies Ltd. (SLGL)

SLGL May 20, 2026

Avg Cost/Share

$64.43

Shares

1,563

Total Value

$100,711.75

Owned After

490,000

SEC Form 4

SLGL Mar 24, 2026

Avg Cost/Share

$72.00

Shares

39,665

Total Value

$2,855,880.00

Owned After

490,000

Share on Social Networks: